Abstract:Background:
It is suspected that patients with multiple sclerosis (MS) are at greater risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to disability and immunotherapy. The relationship between MS and coronavirus disease 2019 (COVID-19) is uncertain. The aim of the study was to collect and analyze this relationship.
Methods:
All MS patients of the Neurological Outpatient Clinic in Zabrze, Poland, were regularly questioned for the symptoms of … Show more
“…In response to the pandemic, we modified the therapeutic protocols of high efficacy therapy, following published expert opinions aimed to reduce the risk of severe infection in susceptible MS patients ( Amor et al, 2020 , Reyes et al, 2021 , Sadeghmousavi and Rezaei, 2020 , Brownlee et al, 2020 , Apostolos-Pereira et al, 2020 , Al Jumah et al, 2021 ). With the wide range of DMTs used in our group, none of them had a severe COVID-19 infection, which is comparable to published reports ( Alahmari et al, 2021 , Alsofayan et al, 2020 , Bsteh et al, 2021 , Capasso et al, 2020 , Nowak-Kiczmer et al, 2021 , Loonstra et al, 2020 ).…”
“…In response to the pandemic, we modified the therapeutic protocols of high efficacy therapy, following published expert opinions aimed to reduce the risk of severe infection in susceptible MS patients ( Amor et al, 2020 , Reyes et al, 2021 , Sadeghmousavi and Rezaei, 2020 , Brownlee et al, 2020 , Apostolos-Pereira et al, 2020 , Al Jumah et al, 2021 ). With the wide range of DMTs used in our group, none of them had a severe COVID-19 infection, which is comparable to published reports ( Alahmari et al, 2021 , Alsofayan et al, 2020 , Bsteh et al, 2021 , Capasso et al, 2020 , Nowak-Kiczmer et al, 2021 , Loonstra et al, 2020 ).…”
“…Our patient reported also mild neurocognitive symptoms lasting approximately 2 months and resolving without specific treatment. Several post-infectious complications of COVID-19 affecting cognitive function (the so-called brain fog) have been described [10]. Mechanisms that may contribute to COVID19-associated neurocognitive symptoms are, at present, unclear.…”
Background Headache is a frequent symptom of the novel coronavirus 19 disease . To date, there are limited information on how COVID-19 affects migraine and its treatment. Case description A 47-year-old patient, suffering from chronic migraine and medication-overuse headache, in September 2020 started erenumab at 70 mg once monthly. Two months later, monthly migraine days decreased from 20 to 5. On the third month, the patient developed mild COVID-19 symptoms, experiencing extreme fatigue, hyposmia, and attention deficit, resulting positive for SARS-Cov-2 RNA. A significant increase in migraine attacks frequency was reported. Brain MRI and EEG were normal. Erenumab was increased to 140 mg/month, and attacks decreased to 3 monthly migraine days and remained stable. All the headaches experienced by our patient during the infection fulfilled the criteria of the migraine attacks, without tensive-like features. Conclusion We report the first case showing the effects of SARS-CoV-2 infection in a patient with chronic migraine and medication-overuse headache treated with erenumab. Our case description suggests that inflammatory processes induced by SARS-CoV-2 infection may increase the frequency of migraine attacks, probably through an activation of the trigeminovascular system. Whether treatment with CGRP receptor antagonist may influence COVID is still debated. Additional studies regarding anti-CGRP monoclonal antibodies in COVID-19 patients are warranted.
“…They speculate that the lymphopenia associated with COVID-19 could, in part, prevent autoreactive memory cells from expanding and initiating relapses through the so-called “bystander effect of SARS-CoV-2 infection” [ 105 ]. Similarly, Nowak-Kiczmer et al, 2021 conclude in their study that SARS-CoV-2 infection was not related to worsening MS in most patients [ 15 ]. Fig.…”
Section: Interaction Covid-19 and Multiple Sclerosismentioning
confidence: 91%
“…SARS-CoV-2 has become a serious challenge for many areas of medicine, including neurology [ 15 ]. In this sense, since the beginning of the pandemic, there has been a special concern for those people suffering from Multiple Sclerosis (MS), especially those who are being treated with disease-modifying therapies (DMTs) [ 16 ], since it is believed that these patients may be at higher risk of infection or of having a more severe course of COVID-19 than the general population.…”
The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
